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Immunisation programmes play a critical role in the advancement 
of the public health of communities. Timely and high-quality 
evidence-informed immunisation policies are critical to strengthen 
immunisation programmes. Therefore, implementation of global, 
regional and national immunisation policies plays an important role 
in combating the burden of vaccine-preventable diseases (VPDs).[1] An 
important policy strategy to combat VPDs in many countries is the 
strengthening of the Expanded Programme on Immunisation (EPI) 
and the introduction of new vaccines. African countries routinely 
lag behind high-income countries in the introduction of new 
vaccines.[2] It is therefore not surprising that in 2016, 10 years after 
human papillomavirus (HPV) vaccine licensure, only a handful 
of African countries had introduced the vaccine.[3] We conducted 
a case study to document the experiences and perspectives of key 
stakeholders during the national HPV vaccine introduction by a few 
African countries.
Although the EPI mainly targets children, adolescents are a new 
target population for vaccination.[4] Because the EPI focuses on 
children, structured delivery of immunisation services to adolescents 
is suboptimal in many African countries.[5] New vaccines that target 
adolescents, e.g. against HPV, are now available.[6] Therefore, there is 
a need to expand the delivery of immunisation services to adolescents 
in all settings. 
African countries are recording a more rapid increase in the 
number of adolescents than countries on other continents.[7] 
Therefore, African policymakers should give HPV immunisation the 
attention it deserves. There is evidence of the benefits of vaccinating 
adolescents, which include boosting of the waning immunity induced 
during childhood.[8,9] Furthermore, initiatives on immunisation, such 
as the Global Immunisation Vision and Strategy (GIVS), Global 
Vaccine Action Plan (GVAP) and Sustainable Development Goals 
(SDGs), all supported the call to extend immunisation services to 
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Background. Infection with human papillomavirus (HPV) significantly increases the risk of developing cervical cancer later in life. 
Therefore, globally, HPV vaccines targeted to pre-adolescent and adolescent girls have been on the rise since the licensure in 2006. However, 
the introduction of HPV vaccines has been relatively slow in Africa. At the end of 2016, only 8 of the 54 countries in Africa were reported 
to have introduced HPV vaccination at a national level. By 2019, the number of countries had grown marginally to 11.
Objectives. To investigate stakeholders’ perspectives on the experiences, challenges and lessons learnt during national HPV vaccine 
introduction in Africa. 
Methods. A questionnaire was administered to selected participants from 8 African countries. These countries had successfully introduced 
HPV vaccination at a national level by the end of 2016. We used in-depth interviews and self-administered online questionnaires for data 
collection and analysis. Data are presented without naming the country or participants; therefore, readers will not be able to identify the 
results that are specific to individual countries. Narrative and thematic reporting were used to describe the results. 
Results. We obtained results from 6 of the 8 targeted countries. The challenges reported during HPV vaccination programmes were: 
identifying the target population, using a school-based vaccine-delivery strategy, obtaining political support, the need to integrate HPV 
vaccination with existing school health programmes and engaging multiple stakeholders. These challenges were similar in all 6 countries. 
The lessons learnt were that a school-based delivery strategy is a successful approach for national HPV vaccination, and that identifying girls 
for vaccination at schools was less challenging if implemented through a class-based instead of an age-based approach.
Conclusions. Most African countries do not have established platforms to deliver vaccines to pre-adolescent and adolescent populations. 
The successful introduction of the HPV vaccine through school-based vaccination strategies in African countries may have created a 
platform to deliver other adolescent vaccines. The similarity of the study findings across the 6 participating countries further strengthens 
the need to document and disseminate the challenges and lessons learnt during HPV vaccine introduction in Africa. Documentation 
and dissemination of the challenges and lessons learnt are useful to other countries in Africa that plan to introduce an HPV vaccination 
programme, and possibly other adolescent vaccines.
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adolescents.[10-12] Therefore, Africa will need to invest more resources 
and develop national immunisation policies that specifically target 
adolescents.
Adolescents are infected with HPV through sexual activity. 
Following HPV infection, there is an increased risk of developing 
cervical cancer later in life.[13] Therefore, a preventive strategy against 
HPV infection aims to vaccinate adolescents before sexual debut. 
Moreover, adolescents are at an increased risk of HIV infection. HIV-
infected men and men who have sex with men have an increased risk 
of anal, penile and throat cancers associated with HPV infection.[14] 
Worryingly, sub-Saharan Africa and Asia have the highest number of 
HIV-positive adolescents.[15] Therefore, HPV vaccination policies in 
Africa should be given due attention to facilitate the introduction of 
the HPV vaccine that targets adolescents.
Slow uptake of new vaccines in Africa is well documented and 
HPV vaccine is not an exception.[16] Girls aged 9 - 13 years are the 
primary target group for HPV vaccination.[17] The rationale for the 
target age group is prior onset of sexual activity and, therefore, 
vaccination before infection with the virus.[18,19] Despite the HPV 
vaccine’s proven safety, efficacy and cost-effectiveness, only 8 African 
countries had reported HPV vaccine introduction at a national 
level by the end of 2016.[20] These were Libya, Lesotho, Rwanda, 
Uganda, South Africa (SA), Botswana, Mauritius and Seychelles.[20] 
By December 2018, 3 additional countries, i.e. Senegal, Zimbabwe 
and Tanzania, reported implementation of a national vaccination 
programme against HPV.[21-23] The delay in HPV vaccine introduction 
in African countries could be due to many reasons, such as the 
current state of the EPI and health systems, resource limitations and 
absence of adolescent immunisation programmes.[24] In this study, we 
evaluated the stakeholders’ perspectives on national implementation 
of a vaccination programme against HPV by 6 African countries.
Specific issues of HPV vaccination delivery include a new target 
population, costs of the vaccine, most optimal delivery strategy 
and advocacy.[18] The national departments of health, funding and 
implementation partners all play a crucial role in the introduction of 
new vaccines. We are aware of other studies that have documented 
experiences and guidelines on HPV vaccine introduction in many 
settings.[25-28] Our study is unique, as we purposefully selected the 
only African countries that had nationally introduced HPV vaccines 
during the study period (2015 - 2016). Also, we purposively selected 
key stakeholders involved in the roll-out of the HPV immunisation 
programme from the 6 participating countries. The selected key 
stakeholders had a broader and high-level view of the programme. 
Our study findings add more context-specific knowledge that is 
useful to other countries planning to nationally introduce HPV 
vaccines in Africa. 
Objectives
To investigate stakeholders’ perspectives during national HPV vaccine 
introduction by African countries.
Methods
Study design and period
We conducted a cross-sectional study between 2015 and 2016. Mixed 
methods (quantitative and qualitative) were used for data collection 
and reporting.
Inclusion criteria
The inclusion criteria comprised all countries in Africa that had 
implemented national HPV vaccination programmes in 2016.
Sample size
This was not a hypothesis testing study. Hence, we did not calculate 
the required sample size. Our target sample size included all countries 
in Africa with national HPV vaccination programmes in 2016. From 
the 8 African countries that had implemented such a programme, one 
key representative (convenient sampling) was invited to participate.
Recruitment of stakeholders
In November 2015, we identified and invited key stakeholders 
representing 5 countries known to have introduced the HPV vaccine 
nationally as per the Global Alliance for Vaccines and Immunisation 
(GAVI) website (https://www.gavi.org/). GAVI supports the financing 
of the HPV vaccine. In November 2016, we invited key stakeholders 
representing 3 additional countries that had nationally introduced 
HPV vaccination in 2016. The selection of stakeholders was done 
through referral sampling (contacts from academics, implementing 
agencies and governments). Key stakeholders were defined as 
members of the National Immunization Technical Advisory Group 
(NITAG), senior officials from the departments of health at national 
level, as well as representatives from international organisations, 
such as the World Health Organization (WHO) and United Nations 
Children’s Fund (UNICEF). 
Questionnaire administration
The questionnaire was developed and pretested for clarity and 
accuracy. During the pretesting process, we also developed a guide 
document with a set of questions aimed at helping the researcher 
to standardise the process of administering the questionnaires, 
especially for open-ended questions. The main domains/areas of 
inquiry in the questionnaire included the following:
• costs of HPV vaccines
• political influence that played a role during introduction of the 
HPV vaccine
• strategies used during HPV vaccination implementation
• factors that hindered introduction of the HPV vaccine
• challenges and lessons learnt during HPV introduction.
One of the study team members (LHA) administered the question-
naires to all participants. Five stakeholders from 5 countries completed 
the questionnaires via face-to-face meetings held in November 2015 
in SA. The last stakeholder from the 6th country could not attend 
the meeting, and therefore completed the questionnaire via email. 
Two stakeholders representing 2 countries were unable to attend the 
meeting or complete the questionnaire via email. 
Missing data
Two representatives from the 7th and 8th countries did not respond 
to the questionnaires sent to them via email. Follow-up telephone 
calls to these representatives were unsuccessful. 
Data management and analysis
Five of the face-to-face interviews were digitally recorded. These 
data were coded with ATLAS version 6 (ATLAS.ti, Germany) for 
analysis. From the questionnaire completed and sent via email, data 
were abstracted for analysis and reporting. Given the small sample 
size, data reporting was blinded to the readership – no naming of 
the country or the participant. Narrative reporting and grouped 
themes were used to describe the results, based on the most common 
words and terms that were similar and repetitively used by key 
representatives.
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Ethical approval 
Prior to the start of the study, ethical approval was obtained from 
the Human Research Ethics Committee (HREC) of the Faculty of 
Health Sciences, University of Cape Town (ref. no. 703/2015). Written 
participation consent forms were obtained from the stakeholders. 
Confidentiality was observed during the interview process with the 
use of blinded transcripts. 
Results
In total, 6 key stakeholders of the 8 targeted stakeholders provided data 
for this study. The 6 representatives were from 6 different countries. 
The descriptive characteristics of the 6 representatives interviewed are 
shown in Table 1. 
From the 6 participants interviewed, information about the 
targeted population for vaccination and the HPV vaccination delivery 
strategy used is provided in Table 2. 
Challenges during the implementation of the national 
HPV vaccination programme
Using data collected from the 6 countries, we grouped the challenges 
and lessons learnt during the implementation of the national HPV 
vaccination programme into themes. Thematic challenges and lessons 
reported by stakeholders were very similar in all 6 countries (Table 3). 
The participants from all the countries reported the following 
challenges: identifying the target population group for HPV 
vaccination, obtaining political support, using a school-based vaccine-
delivery strategy, integrating the HPV vaccination programme 
with existing school health programmes and engaging multiple 
stakeholders.
Identifying the target age group
All the countries represented in this study opted to deliver HPV 
vaccination through the school-based strategy and targeted girls 
only. At the schools, there was a need to correctly identify girls aged 
between 10 and 13 years, who are the target group for HPV. However, 
a challenge was encountered, i.e. whether to use a grade-based or age-
based approach to identify the girls for HPV vaccination. 
For example, during the piloting of HPV vaccination, country A 
(Table 3) started with the age group 9 - 18 years, but due to logistical 
constraints, this target age group could not be optimally reached. 
Hence, some girls missed the intended HPV vaccination at school and 
were referred to the nearest health facility. Subsequently, during the 
national roll-out, all 6 countries reported that the HPV vaccination 
programme was implemented using a class-based approach. This 
approach presumed that the targeted age group (10 - 13 years) would 
be in a given class. The WHO recommends this age group for HPV 
vaccination, and their guidelines stipulate the HPV vaccination 
target group by age.[17] In our study, countries that implemented HPV 
vaccination reported that it was difficult to establish girls’ ages. For 
example, in country B, where 10-year-olds in class 4 were targeted, 
most girls did not have birth records. As a result, it was difficult to 
know which girls in the class were 10 years old.
HPV vaccination schedules were synchronised with the academic 
calendar to avoid loss to follow-up. Furthermore, school teachers 
played a crucial role to assist in the follow-up, and regularly 
communicated information on the vaccination dates to the targeted 
girls. Primary schooling in all 6 participating countries is compulsory; 
hence, the school-based strategy was chosen as the most efficient to 
reach the highest number of targeted girls. The school-based delivery 
strategy was complemented by an outreach strategy, similar to health 
facility strategies, to vaccinate non-schoolgoing girls.
Using the school-based vaccine-delivery strategy
In Africa, as in the rest of the world, the EPI routinely focuses on 
delivering vaccination services to children. In the absence of an 
existing vaccination platform to reach pre-adolescent and adolescent 
girls with HPV vaccines, a new vaccine-delivery strategy was needed. 
During the period of HPV vaccine introduction by African countries, 
there was evidence from high-income countries, e.g. Canada, showing 
that the school-based programme is feasible.[29]
Table 1. Characteristics of key stakeholders interviewed
Country code Type of organisation
Position held
by representative Role in HPV vaccination programme
A Government Programme manager Adviser on implementation of programme
B Government EPI director In charge of implementation of programme
C International organisation New vaccine focal person Adviser on implementation of programme
D Government Programme manager In charge of implementation of programme
E Government Programme manager In charge of implementation of programme
F Government Programme manager In charge of implementation of programme
HPV = human papillomavirus; EPI = Expanded Programme on Immunisation.
Table 2. Characteristics of population targeted for vaccination and delivery strategies used to deliver HPV vaccine
Countries Gender Vaccine-delivery approach Target age group, years
A Female School-based (class-based) approach 9 - 13
B Female School-based (class-based) approach 9
C Female School-based (class-based) approach 10
D Female School-based (class-based) approach 12
E Female School-based (class-based) approach 9 - 13
F Female School-based (class-based) approach 9 - 12
HPV = human papillomavirus.
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Participants in our study reported 
that the introduction of HPV vaccines 
through the school-based strategy 
required the departments of health and 
education to develop a new collaborative 
partnership. The latter involved that the 
departments of health EPI programme 
take the lead with HPV vaccine dem-
onstration initiatives, while the depart-
ments of education led the school-based 
initiatives, such as engagements with 
learners and parents. The co-ordination 
of these interdepartmental initiatives for 
optimal delivery of HPV vaccination was 
reported as a challenge. Prior engage-
ment meetings between officials from 
both departments were necessary to 
ensure complete and on-time dosing of 
HPV vaccines to the targeted girls. Such 
engagement meetings were reported to 
be operationally demanding and time 
consuming.
Obtaining political support 
During the pilot phase, all 6 countries 
reported that the demonstration results 
of the HPV vaccination programme 
were shared with parliamentarians to 
solicit political support. They showed 
interest from the start – the political 
support thus facilitated the necessary 
commitment from government for 
upscaling to national level. The 2014 - 
2020 Africa’s Regional Strategic Plan 
for Immunization was endorsed by 
ministers of health from the region.[30] 
The plan is an example of how political 
will shapes immunisation policies at 
regional and, by extension, national 
level. Country C, for example, reported 
to have received endorsement from 
the national parliament during HPV 
vaccine introduction. In country C, 
the vaccination was launched by the 
First Lady. Due to political support, it 
was possible to expedite the planning 
process, as well as resource mobilisation. 
Political leadership may change after a 
limited period, whereas the vaccination 
programme is a long-term intervention. 
The participants indicated that a possible 
lack of political support in the future 
could compromise the national HPV 
vaccination programme.
Integrating HPV vaccination 
with existing school health pro-
grammes 
Some countries have existing school health 
programmes (such as vision screening, 
deworming and nutritional supplemen-
tation) for school-aged children who may 
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also be the target group for HPV vaccination. Country B, for example, 
reported having a vision screening programme among grade 5 
learners at primary schools. Grade 5 learners were also targeted 
by the HPV vaccination programme in the country. Most of the 
existing school health programmes are characterised by a single visit 
to the institution by the healthcare providers as opposed to HPV 
vaccination that, depending on whether there is administration 
of 2 or 3 doses, requires more than a single visit. Furthermore, 
health service teams from the health department, and not the HPV 
vaccination teams, are involved with the existing school health 
programmes. Two different teams from one department of health 
visiting the same school with different aims was reported as a challenge. In 
country B, for example, there was an observed need to harmonise the 
implementation of these two health programmes (vision screening 
and HPV vaccination). Although this was reported as a challenge 
in terms of logistics, it can also be an opportunity to integrate the 
provision of school health services. Therefore, future plans of many 
countries are to have new school-based health interventions piggyback 
on the HPV vaccination programme, provided the additional logistical 
challenges are addressed.
Engaging multiple stakeholders 
Multiple stakeholder engagement was mentioned as a challenge 
by all participants. Unlike an established EPI, where delivery of 
vaccination services is routinely common and generally accepted, 
HPV vaccination was different in many ways, among these being 
the targeted population (adolescents) and delivery through schools. 
The multiple stakeholders engaged included parliamentarians, key 
officials from the departments of education, school heads and 
teachers, learners and parents. Engaging these multiple stakeholders 
was reported as time consuming and laborious. Obtaining assents 
(from learners) or consents (from parents) for vaccination (which is 
not the case with EPI) was reported as a challenge. 
The participating stakeholders highlighted funding challenges that 
required collaboration of local and international organisations to 
secure complementary financial, technical and operational support. 
Lessons learnt during the implementation of national 
HPV vaccination programmes in 6 countries
Lesson 1. In school, identifying eligible girls for HPV vaccination 
based on grade/class is more feasible than by age. However, some 
eligible girls born after mid-year are likely to be missed during HPV 
vaccination if already in a higher grade. The proportion of the missed 
population needs to be quantified. 
Lesson 2. School-based delivery strategies can be successfully 
used to deliver HPV vaccines to learners in African countries with 
high primary school enrolment. In case of missed vaccination 
opportunities, healthcare facilities can be used as venues for catch-
up vaccinations. Delivery of HPV vaccines through school-based 
programmes may also achieve high coverage levels if there is high-
school enrolment in the targeted age group.
Lesson 3. Obtaining political support during the implementation 
of the HPV vaccination programme is crucial. Political endorsement 
by national and district government leaders is also critical for 
community acceptance.
Lesson 4. Integrating an HPV vaccination programme with existing 
school-based health programmes is a logistical challenge, but also 
an opportunity, as the integration can reduce the costs of health 
programmes delivered to school-aged learners.
Lesson 5. Adequate preparation, engaging diverse and relevant 
stakeholders, including teachers and parents, is crucial to ensure the 
successful implementation of an HPV vaccination programme.
Lesson 6. Additional support from local and international partners 
is needed to ensure sustainability of HPV vaccination programmes. 
Support by local partners is crucial to ensure HPV vaccines reach the 
hard-to-reach populations in a timely manner.
Discussion
In this study, we identified the challenges and lessons learnt 
during the implementation of HPV vaccination programmes. 
Interdepartmental co-ordination, identifying the target age group 
for HPV vaccination, obtaining political support and engaging 
multiple stakeholders were reported as the main challenges. These 
were similar among the African countries that implemented HPV 
vaccination programmes. The similarities of the challenges across 
the study countries were surprising, as the continent’s immunisation 
challenges are not homogeneous.[31] However, generally, countries 
in Africa have many similar competing public health priorities and 
the continent has lagged behind with diphtheria-tetanus-pertussis 
(DTP3) immunisation coverage.[31-33]
The delivery of HPV vaccines to schoolgirls required prior 
engagement and the co-ordination of the departments of health 
and education. Both departments had to plan around the timing of 
vaccinating girls during the school day. Additionally, the departments 
of health had to plan around the logistical delivery of the vaccines and 
transporting health workers to the schools. Despite these challenges, 
our results suggest that good leadership and careful co-ordination 
can overcome these challenges. Furthermore, lessons learnt from this 
co-ordination can be used to integrate existing and future school-
based health interventions with HPV vaccination to expand the 
delivery of vaccines to adolescents.[34,35]
The WHO guidelines recommend the ideal target population 
for HPV vaccination as 9 - 13-year-olds, before onset of sexual 
activity.[17] However, among the participating countries, it was 
difficult to accurately establish the age of the girls before sexual 
activity. This is likely to be the case in many African countries that 
did not participate in the study. Research on sexual debut years for 
adolescents in Africa can guide optimal choice of age to initiate HPV 
vaccination. 
A few African countries that started to pilot HPV vaccination with 
an age-based approach used birthdate records to identify the age 
of girls eligible for vaccination. The age-based approach presented 
a challenge, as the birthdates were often not available on school 
records. However, the challenge with the class-based approach was 
that children who are born mid-year might miss vaccination, as they 
would have moved to the next class not targeted for HPV vaccination. 
Hence, if the missed targeted population is large, the effectiveness of 
HPV vaccination programmes in such countries will be suboptimal, 
not forgetting that boys are not targeted by the programme. The 
approach to select girls for HPV vaccination based on grade as 
opposed to age through a school-based vaccination strategy appeared 
universally ideal in our study. 
The stakeholders alluded to the huge effort needed to obtain 
political support and reach consensus among diverse and key 
stakeholders. In all the participating countries, endorsement of 
the HPV vaccination programme by politicians was a prerequisite. 
Political leadership that understands and embraces the value and 
public health benefits of immunisation is therefore crucial for a 
national HPV vaccination programme in Africa.
Resource mobilisation for HPV vaccination programmes 
required engagement of diverse stakeholders. Broadly, advocacy and 
communication were needed to address this challenge. Many African 
countries, with support from international partners, have made 
considerable progress to strengthen advocacy and communication 
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on immunisation services.[31] However, in Africa, as is the case 
globally, much more effort is still needed to improve advocacy and 
communication with regard to vaccination.[36,37] The lesson learnt 
from this challenge was that the support by local and international 
partners, including politicians, is crucial to initiate and sustain 
HPV vaccination programmes in Africa. The sustainability will 
need strengthened advocacy and communication, not just for HPV 
vaccination, but also for other routine immunisation services.
In this study, primary schooling in all 6 countries was compulsory. 
This made the school-based HPV vaccination strategy the preferred 
method to reach the highest number of targeted girls. However, 
school-based vaccination strategies may not be entirely successful in 
countries with a suboptimal school attendance rate. One study has 
shown that supplementary immunisation activities, including the use 
of outreach health facilities, could be an option to target non-school-
going adolescents.[38]
We propose collaboration among African countries to document 
and share the lessons learnt during the introduction of HPV 
vaccination. A recent study showed high inter-country collaboration 
on immunisation research in Africa.[39] We identified collaborations 
that document and share immunisation research information as 
platforms to foster further discussions on the introduction of other 
adolescent vaccines. The lessons learnt by countries included in this 
study can be of great use to other African countries planning to 
introduce national HPV vaccination programmes. 
Conclusions
All 6 countries used schools as the main site for vaccination. Most 
targeted girls attended school owing to the universal and free primary 
education programme in these countries. Schools therefore provided 
an easy and convenient site to access the eligible population. The 
school team, which included head teachers, teachers and school 
management, embraced the HPV vaccination programme. School 
teams worked closely with the departments of health to ensure that 
there was minimal disruption of classes and that the vaccination 
day does not coincide with important school programmes, such as 
examinations. For situations where targeted learners are inevitably 
absent on vaccination days, a health-facility approach can be used 
to catch up. As African countries continue to introduce HPV 
vaccines nationally, we recommend documentation and sharing of 
experiences. In this way, introduction of HPV vaccines will be guided 
by locally relevant experiences.
Study limitations and validity 
Of 54 African countries, findings for this study are from 6 countries 
only for reasons provided in the abovementioned methods section. 
This limitation is further compounded by having interviewed only one 
representative per country. Therefore, extrapolation of the findings to 
the entire continent must be done with caution. Another limitation 
is the use of questionnaires alone to collect data, without conducting 
focus group discussions. This was because of resource limitations.
Study strengths
• The study focus is on countries in Africa implementing HPV 
vaccination. This has not been evaluated before by using a similar 
methodology to ours. Although few countries are represented, the 
experiences are rich and useful in the African context.
• There is a paucity of knowledge on adolescent immunisation in 
Africa. Therefore, this study contributes to the knowledge base in 
the field.
• Documentation and dissemination of the challenges and lessons 
learnt are useful to other countries in Africa that plan to introduce 
the HPV vaccination programme.
Study weaknesses
• HPV implementation in Africa is a new concept and its 
implementation is slow – therefore the small sample size. We have 
also not included the countries that have recently (2018 and 2019) 
introduced HPV vaccination. 
• The respondents gave similar experiences and challenges of a 
school-based programme as a successful platform. Therefore, the 
study might not have information for the countries that need to 
attempt other methods of implementing HPV vaccination, such as 
health-facility-based programmes.
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